Close Menu

NEW YORK – Singaporean firms Inex Innovations and Exchange and Nova Satra Dx this week announced their merger and decision to focus on offering diagnostic testing and precision healthcare to Asian women.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women. The deal is valued at $72 million and is backed by investors including Kuala Lumpur, Malaysia-based Genting, as well as Enterprise Singapore and SNS Holdings, both based in Singapore.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.